The clinical objective with Veyonda® is to deliver a form of immuno-oncology therapy considerably better tolerated, more accessible, more cost-effective and more broadly active than current forms of immuno-oncology therapy
DARRT relies on a low dose of radiotherapy to provide the trigger for immune activation, with the role of Veyonda® being to amplify and spread that response to tumours throughout the body.
The DARRT-2 study is a multi-national Phase 2 control-arm study in approximately 200 men with end-stage metastatic castrate-resistant prostate cancer.
Hospital and clinician recruitment will now commence, with all regulatory and ethical approvals to follow. Patient recruitment is anticipated to commence early in the New Year. The trial has a number of in-built milestones that will be reported on over the course of the study.
NOX Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
